Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors
- PMID: 17405969
- DOI: 10.1001/jama.297.13.1435
Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors
Abstract
Context: Very little is known about the frequency of generation and transmissibility of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Furthermore, transmission of resistant virus, whether influenza A or B, has not been recognized to date.
Objective: To assess the prevalence and transmissibility of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
Design, setting, and patients: Investigation of the neuraminidase inhibitor sensitivity of influenza B isolates from 74 children before and after oseltamivir therapy and from 348 untreated patients with influenza (including 66 adults) seen at 4 community hospitals in Japan during the 2004-2005 influenza season. Four hundred twenty-two viruses from untreated patients and 74 samples from patients after oseltamivir therapy were analyzed.
Main outcome measure: Sialidase inhibition assay was used to test the drug sensitivities of influenza B viruses. The neuraminidase and hemagglutinin genes of viruses showing reduced sensitivity to neuraminidase inhibitors were sequenced to identify mutations that have the potential to confer reduced sensitivity to these drugs.
Results: In 1 (1.4%) of the 74 children who had received oseltamivir, we identified a variant with reduced drug sensitivity possessing a Gly402Ser neuraminidase substitution. We also identified variants with reduced sensitivity carrying an Asp198Asn, Ile222Thr, or Ser250Gly mutation in 7 (1.7%) of the 422 viruses from untreated patients. Review of the clinical and viral genetic information available on these 7 patients indicated that 4 were likely infected in a community setting, while the remaining 3 were probably infected through contact with siblings shedding the mutant viruses.
Conclusions: In this population, influenza B viruses with reduced sensitivity to neuraminidase inhibitors do not arise as frequently as resistant influenza A viruses. However, they appear to be transmitted within communities and families, requiring continued close monitoring.
Comment in
-
News about influenza B drug resistance that cannot be ignored.JAMA. 2007 Apr 4;297(13):1492-3. doi: 10.1001/jama.297.13.1492. JAMA. 2007. PMID: 17405975 No abstract available.
Similar articles
-
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17. Antiviral Res. 2013. PMID: 23791870
-
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.J Infect Chemother. 2014 Feb;20(2):77-80. doi: 10.1016/j.jiac.2013.07.002. Epub 2013 Dec 11. J Infect Chemother. 2014. PMID: 24560563
-
Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.Antivir Ther. 2009;14(6):751-61. doi: 10.3851/IMP1194. Antivir Ther. 2009. PMID: 19812437
-
Influenza virus susceptibility and resistance to oseltamivir.Antivir Ther. 2007;12(4 Pt B):603-16. Antivir Ther. 2007. PMID: 17944268 Review.
-
Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Expert Rev Anti Infect Ther. 2011. PMID: 21973296 Review.
Cited by
-
Human SUMOylation Pathway Is Critical for Influenza B Virus.Viruses. 2022 Feb 3;14(2):314. doi: 10.3390/v14020314. Viruses. 2022. PMID: 35215907 Free PMC article.
-
Antivirals for influenza: strategies for use in pediatrics.Paediatr Drugs. 2010 Oct 1;12(5):285-99. doi: 10.2165/11532530-000000000-00000. Paediatr Drugs. 2010. PMID: 20799758 Review.
-
Lessons from resistance analysis in clinical trials of IV zanamivir.Virus Res. 2023 Feb;325:199039. doi: 10.1016/j.virusres.2023.199039. Epub 2023 Jan 4. Virus Res. 2023. PMID: 36610656 Free PMC article. Clinical Trial.
-
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada.Emerg Infect Dis. 2019 Apr;25(4):838-840. doi: 10.3201/eid2504.181554. Emerg Infect Dis. 2019. PMID: 30882323 Free PMC article.
-
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.Antimicrob Agents Chemother. 2009 Jan;53(1):186-92. doi: 10.1128/AAC.00333-08. Epub 2008 Oct 27. Antimicrob Agents Chemother. 2009. PMID: 18955520 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical